Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study
Gerardo Rosati(Ospedale San Carlo), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), M. Cinausero(University of Udine), Silvia Brugnatelli(Policlinico San Matteo Fondazione), Giorgio Reggiardo(Data Management (Italy)), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Domenico Corsi(Ospedale San Carlo), Giuseppe Cicero(University of Palermo), Chiara Carlomagno(Federico II University Hospital), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Stefania Rapisardi(Ospedale Garibaldi), Emanuela Dell’Aquila(Università Campus Bio-Medico), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Alfredo Colombo
Cited by 5
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k